A study in adults testing a unani formulation to evaluate its safety and effectiveness in treating Rheumatoid arthritis

A randomized parallel group, open labelled active controlled clinical study to evaluate the safety and efficacy of habb-e-hindi in the management of waja-ul- mafasil murakkab (rheumatoid arthritis) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100679

Enrollment

Registered

2026-01-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M068- Other specified rheumatoid arthritis

Interventions

Intervention1: Habb E Hindi: Habb E Hindi Dosage form: tablet Dose: 2.5 g bid with water after meals for 60 days with 4 follow ups at interval of 15 days Composition of Unani Formulation Habb E Hi

Eligibility

Inclusion criteria

Inclusion criteria: Age group above 18 to 60 years sex: Both RA factor positive ACPA positive ACR 2010 Criteria more than 6

Exclusion criteria

Exclusion criteria: Other joint diseases,Patient with uncontrolled HTN, DM, CVS, Hepatic, Renal, Pulmonary diseases,Pregnant and lactating women,Drug or Alcohol addicts,H/o Intra articular corticosteroids drugs,Other Autoimmune diseases

Design outcomes

Primary

Measure	Time frame
Change in DAS 28 Score from baseline to 2nd,4th,6th and 8th week post treamentTimepoint: Change in DAS 28 Score from baseline to 2nd,4th,6th and 8th week post treament	—

Secondary

Measure	Time frame
Changes in ESR,RA factor,ACPA,CBP,LFT,KFT From baseline to 4th week and 8th week Timepoint: Changes in ESR,RA factor,ACPA,CBP,LFT,KFT From baseline to 4th week and 8th week	—

Countries

India

Contacts

Public ContactDr Mede Ramesh

Government Nizamia Tibbi College

drfaroqui@gmail.com9849139356

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026